SOURCE: Healtheuniverse, Inc.

March 14, 2007 13:15 ET

Healtheuniverse Re-Releases Shareholder Letter Highlighting Adult Stem Cell Clinical Initiatives

COVINA, CA -- (MARKET WIRE) -- March 14, 2007 -- Healtheuniverse, Inc. (PINKSHEETS: HLUN), a biotechnology development firm engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells, today re-released a letter to shareholders. In the letter, Chief Executive Officer Dr. Vipul Dev M.D. summarizes the Company's recent accomplishments during the first few months of 2007 and cites key goals for Healtheuniverse's adult stem cell and regenerative medicine clinical development programs.

Dear Fellow Shareholders:

"These past few months have been dedicated to strengthening the foundation for Healtheuniverse's clinical launch phase, and I want to draw your attention to some key Company milestones announced in recent press releases that you may not have seen. With our vision for commercialized therapies utilizing non-embryonic stem cells, we've introduced a strategy for addressing critical areas of delivering stem cell therapies that can be utilized internationally and profitably. These therapies will target five key market segments -- Plastic, Reconstructive and Cosmetic Surgery, Orthopedic Surgery, Vascular Surgery, Cardiac Surgery, and Wound Care. Our short term goal and first clinical trial is focused on making Healtheuniverse the first Corporation to commercialize the use of adult stem cells in plastic and reconstructive surgery and to bring the medical promise of stem cell therapies to patients in this pioneering field of medicine.

In support of this clinical effort we have announced an exclusive agreement for plastic, reconstructive, and cosmetic surgery clinical trials with the California Institute of Cosmetic and Reconstructive Surgery, a clinical medical practice focused on the latest techniques in Cosmetic Surgery and extensive new developments in the field of Reconstructive Surgery. CICRS has and continues to deliver a strong reputation in the market for delivering best-in-class Cosmetic Surgery applications such as breast augmentation, facelifts, liposuction, and rhinoplasty, as well as extensive Reconstructive Surgery for Breast Cancer, burn victims, trauma victims, chronic wounds, skin cancer, and hand surgery. CICRS also shares Healtheuniverse's vision for an approach to delivering the first adult stem cell based therapies that spans the entire market for plastic and reconstructive surgery. This alliance adds a vital component to our overall strategy and provides the cornerstone of our adult stem cell based commercialization model.

International and large scale pre-clinical and clinical adult stem cell development has been moving forward quickly with the incorporation of a new wholly owned subsidiary in Singapore, Healtheuniverse Pte Ltd. This corporate infrastructure with a planned full scale adult stem cell research and development center has been achieved with an alliance and support from the Economic Development Board of Singapore (EDB).

In summary, Healtheuniverse continues to move forward with development of pre-clinical and clinical initiatives to commercialize non-embryonic adult stem cell therapies. For 2007, the key clinical activities for the company will be: 1) advancing the cosmetic, plastic, and reconstructive clinical trials and commercializing the first therapy of its kind in this market segment 2) advancing the pre-clinical research of wound care and disease related adult stem cell applications for use in orthopedic, vascular, and cardiac surgery.

I look forward to providing you with further updates on our clinical trial development activities in the coming months, as we enter into what looks to be an exciting year for Healtheuniverse."


HEALTHeUNIVERSE, Inc. is engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in disease related commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact